Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04684485 · ClinicalTrials.gov registry record · Phase 2
To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT04684485 is a Phase 2 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 250 participants.
The verdict
NCT04684485, a Phase 2 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.
Interventions
- DRUG Placebo
- DRUG SCD-044_Dose 1
- DRUG SCD-044_Dose 2
- DRUG SCD-044_Dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2021-07-30 |
| Est. Completion | 2025-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04684485
The ClinicalTrials.gov registry entry for NCT04684485 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04684485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04684485 about?
NCT04684485 is a clinical study titled "To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis". This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.
What is the current status of trial NCT04684485?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2021-07-30. Estimated completion is 2025-03-18.
What interventions are being tested in trial NCT04684485?
The interventions under investigation include: Placebo (DRUG), SCD-044_Dose 1 (DRUG), SCD-044_Dose 2 (DRUG), SCD-044_Dose 3 (DRUG).
Who is sponsoring clinical trial NCT04684485?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.